



Chang et al. Cardiovascular Diabetology 2014, 13:91
http://www.cardiab.com/content/13/1/91ORIGINAL INVESTIGATION Open AccessDifferent angiotensin receptor blockers and
incidence of diabetes: a nationwide
population-based cohort study
Chia-Hsuin Chang1,2,3†, Yi-Cheng Chang2,3,4†, Li-Chiu Wu1, Jou-Wei Lin3,5*, Lee-Ming Chuang1,2,3* and Mei-Shu Lai1Abstract
Background: Angiotensin receptor blockers (ARBs) have been shown to exert various peroxisome proliferator-activated
receptor gamma (PPARγ) binding activities and insulin-sensitizing effects. The objective of this study was to investigate
the association of different ARBs with new-onset diabetes mellitus.
Methods: In the respective cohort, a total of 492,530 subjects who initiated ARB treatment between January 2004 and
December 2009 were identified from Taiwan National Health Insurance Database. The primary outcome was newly
diagnosed diabetes, defined as at least one hospital admission or two or more outpatient visits within a year with an
ICD-9-CM code 250. Cox proportional regression was used to estimate the risk of diabetes associated with each ARB,
using losartan as the reference.
Results: A total of 65,358 incident diabetes cases were identified out of 1,771,173 person-years. Olmesartan initiators had
a small but significantly increased risk of developing diabetes after adjusting for baseline characteristics and mean daily
dose (hazard ratio [HR], 1.07; 95% confidence interval [CI], 1.03-1.12). After excluding those followed for less than one
year, the increase in diabetes risk are more pronounced (HR, 1.09; 95% CI, 1.05-1.14). This association was consistent
across all subgroup analyses. Similar results were observed when a more strict definition of diabetes combining both
diabetes diagnosis and anti-diabetic treatment was used. On the other hand, there was no difference in diabetes risk
between telmisartan and losartan.
Conclusions: Among all ARBs, olmesartan might be associated with a slightly increased risk of diabetes mellitus. Our
data suggest differential diabetes risks associated with ARBs beyond a class effect.
Keywords: Angiotensin receptor antagonists, Diabetes mellitus, Cohort studiesIntroduction
Angiotensin II type 1 receptor blockers (ARBs) are widely
used for treatment of hypertension and congestive heart
failure. Several meta-analyses, randomised clinical trials or
retrospective studies have demonstrated that ARBs use re-
duces diabetes risk in patients with hypertension or con-
gestive heart failure as compared to other antihypertensive
therapies or placebo [1-16]. Since hypertension is often as-
sociated with insulin resistance and impaired glucose* Correspondence: jouweilin@yahoo.com; leeming@ntu.edu.tw
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unless otherwise stated.tolerance, the metabolic effect of anti-hypertensive agents
is viewed as an important consideration for choosing
initial therapy. Accordingly, the UK National Institute
for Health and Clinical Excellence now recommends
ACE inhibitors and ARBs as the first-line antihypertensive
drugs treatment partly because of their beneficial meta-
bolic effects [4].
The anti-diabetic action of ARBs appears to be complex,
including activation of peroxisome proliferator-activated
receptor-γ (PPARγ), suppression of oxidative stress, in-
hibition of fibrosis, and enhancement of insulin signal-
ling [17,18]. There is substantial difference in the chemical
structure and lipid solubility among ARBs [19]. Further-
more, different ARBs had different degrees of PPARγ
agonist activities. Telmisartan has highest PPARγ agonistLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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losartan, valsartan and olmesartan seem to possess little
PPARγ agonist activity [20-23]. The heterogeneity among
ARBs might affect their metabolic action. Since there is
currently no study comparing the risk of diabetes associ-
ated with individual ARBs, the objective of this study was




A single-payer and compulsory National Health Insurance
(NHI) program was implemented in Taiwan since 1995.
The enrollment rate was 99% in 2010. The Taiwan NHI
database includes complete outpatient visits, hospital ad-
missions, prescriptions, disease and vital status for 99%
of total Taiwan population (approximately 23 million).
Several computerized claims datasets were linked with
the National Death Registry through the use of birth dates
and civil identification numbers unique to each beneficiary.
The protocol of this study was approved by the National
Taiwan University Hospital Research Ethics Committee.
Study population
From the source population, we identified adult patients
aged more than 20 years who initiated losartan, valsar-
tan, irbesartan, candesartan, telmisartan, or olmesartan
treatment (anatomical therapeutic chemical [ATC] clas-
sification system codes were provided in Additional file 1:
Table S1) between January 1, 2004 (when the above ARBs
were all reimbursed by NHI) and December 31, 2009. Ini-
tiation was defined as free of any prescription of ARBs or
ACE inhibitors 12 months prior to the first prescription
(index date). Exclusion criteria were the patients 1) aged
more than 100 years, 2) who did not have continuous
NHI coverage 12 months before the index date, 3) who
received more than one ARBs or ACE inhibitors on
the index date, 4) who had diabetes diagnosis or received
anti-diabetic therapy (insulin or oral anti-diabetic agents)
before the index date, and 5) who already had cancer diag-
nosis before the index date.
Use of study drugs
We collected information of prescribed drug types, dos-
age, date of prescription, supply days, and total number
of pills dispensed from the pharmacy prescription data-
base. Every person-day during study period was classified
into current use and nonuse. Current use was defined as
use during the period between the prescription start date
and the end of the days of supply. Cumulative dosage of
ARBs during the study period was calculated and pre-
sented as the defined daily dose (DDD), which was estab-
lished by an expert panel according to the relative amount
compared to the typical maintenance dose for an adult(DDDs: 50 mg for losartan, 80 mg for valsartan, 150 mg
for irbesartan, 8 mg for candesartan, and 40 mg for telmi-
sartan) [24]. Subsequently, the average daily dose for each
individual was calculated by dividing the cumulative dos-
age by the follow-up duration.
Outcome ascertainment
The primary outcome was diabetes incidence. Patients
were classified as having newly diagnosed diabetes if
they had at least one hospital admission with a diagnos-
tic code of diabetes (The International Classification of
Diseases, 9th Revision, Clinical Modification, ICD-9-CM
code 250) or two or more outpatient visits with diabetic
diagnostic code within a year. This definition of diabetes
was evaluated by a study sampling 9,000 patients with a
diagnosis of diabetes in the NHI claims data in 2000.
Validation of this algorithm demonstrated a high level of
sensitivity and positive predictive value (93.2% and 92.3%,
respectively) [24].
Covariate ascertainment and adjustment
We used inpatient and outpatient diagnosis files and
prescription file during the 12-month period before the
index date to ascertain patients’ history of hypertension,
cardiovascular, cerebrovascular, peripheral vascular dis-
ease, chronic kidney, liver, and lung disease, and depres-
sion (ICD-9-CM codes provided in Additional file 1:
Table S1) as well as the use of anti-platelet agents, anti-
coagulants, alpha-blockers, beta-blockers, calcium chan-
nel blockers, diuretics, other anti-hypertensive agents,
nitrates, statins, fibrates, digitalis, anti-arrhythmic agents,
cyclooxygenase-2 selective and non-selective non-steroidal
anti-inflammatory drugs (NSAID) (ATC codes provided in
Additional file 1: Table S1). We also collected patients’ in-
formation on age, sex, and patients’ resource utilization
(number of outpatient visits, number of hospitalizations,
number of laboratory test measurements) 12 months prior
to the index date.
Statistical analysis
Baseline characteristics, co-morbidities, medication use,
and resource utilization among individual ARB initiators
were presented. We computed their person-days of
follow-up in each ARB use category. The crude incidence
rates of diabetes and their 95% confidence intervals (CIs)
were estimated based on a Poisson distribution. In the
main analysis, we followed all ARBs users until the new
onset of DM, death, disenrollment from the national
health insurance, or study end (last outpatient visit or
hospitalization before December 31, 2010). This intention-
to-treat (ITT) analysis, analogous to ITT approach in
randomized controlled trials, was based on the initial
treatment assignment and not on the treatment even-
tually received. No matter how the medication had
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the initial ARB treatment group [25,26]. Cox proportional
hazards regression model was used to calculate the hazard
ratios [27] and their 95% CI with losartan as the common
reference group. In the multivariable analysis, stepwise
selection was used to control for variables with p values <
0.10 for model entry and > 0.05 for removal. In addition,
time-varying covariate for mean daily dosage of ARB use
was also adjusted in the multivariable regression model to
control for the potential effect of dosage.
In the sensitivity analyses, we investigated whether ef-
fect estimates would change in response to more strict
definition of outcome (which combined both diabetes
diagnosis and anti-diabetic treatment) and exclusion of
patients that were followed less than one year. Addition-
ally, stratified analyses were performed to evaluate po-
tential effect modification. Participants were further stratified
according to 1) age (< 70, ≥ 70 years), 2) gender (men,
women), and 3) whether having hypertension at theFigure 1 Study flow diagram.beginning. A test of interaction was performed using like-
lihood ratio test. Two-sided p value < 0.05 was considered
to be statistically significant. All statistical analyses were
performed with SAS 9.2 (SAS Institute, Cary, NC).
Auxiliary analyses were then conducted to compare
the associations between ARB use and new onset DM
among exclusive users who remained on the initial treat-
ment throughout the follow-up course. This was used to
examine whether the results changed substantially in
comparison to the main ITT approach, as a measure of
internal consistency.
Results
A total of 492,530 ARBs initiators fulfilling the criteria
were included in the analysis (Figure 1). The baseline char-
acteristics for each ARB initiator is listed in Table 1. As
shown in Table 1, groups of ARBs initiators differed in a
number of baseline characteristics. Telmisartan and olme-
sartan initiators had a higher proportion of hypertension,
Table 1 Baseline characteristics, comorbidities, medication use, and resource utilization 12 months before study entry
among initiators of different angiotensin receptor blockers
Losartan Valsartan Irbesartan Candesartan Telmisartan Olmesartan
Number of patients 127,383 183,486 80,845 39,430 35,017 26,369
Patient characteristics
Age at ARBs initiation
(mean ± SD)
59.55 ± 14.39 60.00 ± 14.41 59.20 ± 14.39 59.67 ± 14.35 58.82 ± 14.12 58.45 ± 14.28
Male (%) 52.64 52.88 54.12 52.88 52.67 54.96
Initiation year (%)
2004 21.16 23.23 25.33 7.22 21.06 0.88
2005 14.87 18.52 18.68 10.06 15.53 9.15
2006 11.54 15.59 15.97 17.58 13.72 14.77
2007 12.52 14.84 14.27 21.41 16.91 20.40
2008 19.21 13.60 13.42 22.74 16.57 27.46
2009 20.71 14.23 12.33 20.99 16.20 27.34
Comorbidities (%)
Hypertension 87.05 88.36 88.68 85.87 90.72 91.20
Ischemic heart disease 19.19 20.78 19.80 27.30 19.76 18.22
Myocardial infarction 0.91 1.03 0.90 1.24 0.76 0.53
Heart failure 5.31 6.21 5.15 8.34 3.99 3.30
Atrial fibrillation 2.37 2.19 2.18 3.06 1.35 1.21
Cerebrovascular disease 11.01 14.17 14.68 11.32 11.91 11.08
Ischemic stroke 6.08 7.72 8.06 5.91 5.88 5.74
Intracerebral hemorrhage 1.13 2.30 2.16 1.36 1.53 1.39
Peripheral vascular disease 0.05 0.04 0.03 0.03 0.06 0.04
Chronic renal failure 3.48 3.15 4.28 2.10 2.51 2.24
Chronic liver disease 10.62 10.37 10.55 10.99 10.42 10.12
Chronic lung disease 17.12 18.04 16.80 17.22 16.22 16.43
Depression 4.08 4.28 4.30 4.18 4.18 4.00
Charlson’s index (mean ± SD) 0.78 ± 1.03 0.83 ± 1.05 0.84 ± 1.06 0.78 ± 1.01 0.73 ± 0.99 0.68 ± 0.95
Number of different ICD-9
diagnoses (mean ± SD)
13.62 ± 7.69 13.74 ± 7.74 13.37 ± 7.57 13.63 ± 7.70 13.21 ± 7.54 13.21 ± 7.59
Number of cardiovascular-related
diagnoses (mean ± SD)
1.60 ± 1.10 1.71 ± 1.15 1.70 ± 1.15 1.79 ± 1.15 1.66 ± 1.07 1.59 ± 1.01
Medication use (%)
Aspirin 28.39 31.83 29.27 31.48 27.88 27.62
Clopidogrel 2.32 2.90 3.12 3.83 2.28 1.85
Warfarin 1.36 1.33 1.25 1.66 0.92 0.86
Alpha-blockers 4.99 5.04 5.50 4.30 5.24 4.97
Beta-blockers 40.82 43.54 45.64 47.42 44.46 41.56
Calcium channel blockers 56.13 59.86 61.55 60.50 60.12 62.00
Diuretics 26.63 27.82 27.89 26.65 24.85 23.47
Other anti-hypertensive agents 1.54 1.84 2.04 1.48 1.68 1.56
Nitrates 10.87 12.83 11.68 15.74 10.91 9.79
Statins 12.02 11.81 13.64 15.55 13.16 12.21
Fibrates 4.17 4.22 4.54 4.45 4.70 4.08
Digitalis glycoside 3.15 3.40 2.64 3.45 2.08 1.72
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Table 1 Baseline characteristics, comorbidities, medication use, and resource utilization 12 months before study entry
among initiators of different angiotensin receptor blockers (Continued)
Antiarrhythmics class I and III 3.30 3.33 3.35 4.15 2.52 2.43
COX-2 non-selective NSAIDs 76.74 75.97 74.47 73.31 74.47 75.58
COX-2 selective NSAIDs 7.49 8.24 8.47 7.32 7.12 5.94
Number of different prescription
drugs (mean ± SD)
24.46 ± 15.72 25.41 ± 16.34 24.48 ± 15.93 23.69 ± 15.46 23.62 ± 15.61 23.48 ± 15.32
Number of cardiovascular-related
medications (mean ± SD)
3.53 ± 2.20 3.76 ± 2.32 3.79 ± 2.31 3.83 ± 2.32 3.65 ± 2.23 3.58 ± 2.20
Resource utilization (mean ± SD)
Number of A1C measurement 0.04 ± 0.20 0.04 ± 0.19 0.05 ± 0.21 0.06 ± 0.24 0.05 ± 0.21 0.04 ± 0.21
Number of lipid-related lab test 1.12 ± 1.47 1.20 ± 1.48 1.42 ± 1.53 1.68 ± 1.59 1.47 ± 1.56 1.37 ± 1.57
Number of cardiac ultrasound
examination
0.15 ± 0.42 0.17 ± 0.46 0.18 ± 0.49 0.34 ± 0.65 0.19 ± 0.47 0.15 ± 0.44
Number of outpatient visits 25.62 ± 20.22 25.40 ± 20.37 24.96 ± 19.83 25.21 ± 19.99 24.32 ± 19.51 24.38 ± 20.08
Number of emergency department visit 0.41 ± 1.01 0.49 ± 1.20 0.47 ± 1.09 0.48 ± 1.21 0.42 ± 1.00 0.43 ± 0.97
Number of cardiology outpatient visits 1.59 ± 3.67 1.73 ± 3.70 2.15 ± 4.08 3.01 ± 4.62 2.09 ± 3.96 1.69 ± 3.57
Number of cardiovascular-related
physician visits
5.82 ± 6.75 6.08 ± 6.98 6.23 ± 6.85 6.35 ± 6.88 5.98 ± 6.84 5.77 ± 6.68
Coronary revascularization % 0.44 0.57 0.49 1.03 0.39 0.49
Number of hospitalizations 0.23 ± 0.63 0.29 ± 0.69 0.28 ± 0.66 0.27 ± 0.64 0.22 ± 0.61 0.25 ± 0.65
Number of hospitalizations due to
cardiovascular-related diseases
0.13 ± 0.43 0.17 ± 0.48 0.16 ± 0.47 0.16 ± 0.45 0.13 ± 0.43 0.14 ± 0.44
Number of hospital days 2.47 ± 16.01 3.01 ± 16.33 2.79 ± 14.54 2.46 ± 13.96 2.15 ± 13.53 2.57 ± 17.20
Number of cardiovascular-related
hospital days
1.23 ± 8.39 1.69 ± 9.61 1.61 ± 8.82 1.34 ± 6.89 1.17 ± 7.32 1.35 ± 9.37
ARB: angiotensin receptor blockers.
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failure, while olmesartan initiators were more likely to re-
ceive calcium channel blockers but less likely to receive
anti-platelet and beta-blockers therapy. In contrast, cande-
sartan initiators had a higher proportion of ischemic heart
disease and heart failure, and were more likely to receive
anti-platelet agents, beta-blockers, nitrates, and statins.
Meanwhile, higher proportion of valsartan and irbesartan
initiators had cerebrovascular disease and ischemic stroke.
The mean follow-up duration was 3.59 years. During a
total of 1,771,173 person-years of follow-up, 65,358 inci-
dent diabetes cases were identified. The crude incidenceTable 2 Person-days and crude incidence rates of diabetes am
Losartan Valsartan
Exposed person-days 160,956,721 252,964,999
Mean follow-up days 1263.57 1378.66
Mean treatment duration (days) 312.03 349.32
Mean daily dosage (DDD) 0.36 0.39
Number of newly diagnosed
diabetes
16,227 25,849





(100.94-103.43)rates of diabetes for different groups of ARB initiators are
shown in Table 2. The crude HR of diabetes was higher
for olmesartan initiators as compared with losartan initia-
tors (HR, 1.35; 95% CI: 1.29-1.40, Table 3). After adjusting
for differences in baseline characteristics, diabetes risk as-
sociated with olmesartan initiators remained significantly
higher (adjusted HR, 1.07; 95% CI: 1.03-1.12, Table 3). The
results were similar after further adjustment for mean
daily dose (Table 3). After excluding those followed for
less than one year, the crude and adjusted HR associated
with olmesartan initiators increased to 1.48 (95% CI: 1.41-
1.55) and 1.09 (95% CI: 1.05-1.14), respectively (Table 3).ong initiators of angiotensin receptor blockers
Irbesartan Candesartan Telmisartan Olmesartan
115,243,240 44,349,122 46,800,437 26,163,756
1425.48 1124.76 1336.51 992.22
379.50 344.67 329.76 271.00
0.39 0.41 0.42 0.37









Table 3 Hazard ratios of diabetes incidence comparing individual angiotensin receptor blocker with losartan
Valsartan Irbesartan Candesartan Telmisartan Olmesartan
All subjects
Crude 0.99 (0.97-1.01) 0.95 (0.93-0.97) 1.13 (1.09-1.17) 0.98 (0.95-1.01) 1.35 (1.29-1.40)
Multivariable regression analysis 1.01 (0.99-1.03) 0.99 (0.97-1.02) 0.99 (0.96-1.03) 0.99 (0.96-1.03) 1.07 (1.03-1.12)
Multivariable regression adjusted for mean daily dosage 1.01 (0.99-1.03) 0.99 (0.97-1.01) 0.99 (0.96-1.02) 0.99 (0.96-1.02) 1.07 (1.03-1.12)
Excluding those followed for less than one year
Crude 1.00 (0.98-1.02) 0.97 (0.94-0.99) 1.18 (1.14-1.23) 1.00 (0.96-1.03) 1.48 (1.41-1.55)
Multivariable regression analysis 1.02 (1.00-1.04) 1.01 (0.98-1.03) 1.00 (0.96-1.04) 1.00 (0.96-1.03) 1.09 (1.04-1.14)
Multivariable regression adjusted for mean daily dosage 1.02 (1.00-1.04) 1.00 (0.98-1.03) 0.99 (0.96-1.03) 1.00 (0.96-1.03) 1.09 (1.05-1.14)
Multivariable regression analysis: adjusted for baseline covariates by traditional multivariable regression with stepwise variable selection.
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been shown to possess potent PPARγ activity were not as-
sociated with altered diabetes risk.
In the stratified analysis, we found that the increased
HR of diabetes associated with olmesartan initiators was
consistent across all subgroups (Table 4). In sensitivity
analysis using strict diabetes definition (diagnosis code
plus anti-diabetic treatment), olmesartan was still associ-
ated with an increased risk (Additional file 1: Table S2).
Furthermore, a decreased diabetes risk was also found for
candesartan initiator using this strict diabetes definition
(HR, 0.91; 95% CI: 0.87-0.95, Additional file 1: Table S2).
The auxiliary analyses, which included only exclusive
users who maintained the initial ARB throughout the
follow-up period, showed similar results as compared to
the main ITT approach. For example, the new DM risk
was also slightly increased in olmesartan than in losartan
(Additional file 1: Table S3).
Discussion
Clear evidence indicated that the protective effects of
ARBs against progression to diabetes were superior to
those of placebo or other active anti-hypertensive treat-
ment [1-16]. Meta-analyses showed that, overall, ARBs
were associated with a 15 ~ 25% reduction in the risk of
diabetes [3,28]. However, no solid evidence shows that
all ARBs pose the same protective effect against diabetes.
Instead, our findings indicate differential associations ofTable 4 Adjusted hazard ratios of diabetes incidence compar
among different subgroups
Valsartan Irbesartan
Age < 70 years 1.01 (0.99-1.04) 1.01 (0.98-1.04)
Age≧ 70 years 1.00 (0.96-1.04) 0.95 (0.91-0.99)
Men 0.99 (0.97-1.02) 0.98 (0.95-1.01)
Women 1.03 (1.00-1.06) 1.01 (0.97-1.04)
With hypertension 1.01 (0.99-1.03) 0.98 (0.96-1.01)
Without hypertension 1.02 (0.96-1.08) 1.07 (0.99-1.15)ARBs with diabetes risk. In a large nationwide cohort,
we found that olmesartan posed a slightly higher dia-
betes risk while candesartan seem to be associated with
reduced diabetes risk.
Our data was in part in line with previous studies
showing consistent protective effects of candesartan on
diabetes risk. In comparison with placebo, candesartan
therapy was associated with fewer newly diagnosed dia-
betes in patients with heart failure [5] and possibly also
in the elderly patients [6]. When compared with active
treatment (i.e., amlodipine and non-ARB antihypertensive
agents), candesartan was also associated with a lower risk
of diabetes in hypertensive patients with or without coron-
ary artery disease [10,11].
Previous studies demonstrated that ARBs possess vari-
ous PPARγ activation activities. Telmisartan seems to have
strongest activity, followed by candesartan and irbesartan;
while other ARBs have little activities [20-23]. In our
study, however, telmisartan was not associated with lower
diabetes incidence as expected. This is consistent with a
large randomized clinical trial showing no effect of telmi-
sartan on diabetes incidence as compared to placebo [29].
The explanation for this discrepancy is not clear but may
be due to pleiotropic effects of ARBs on glucose metabol-
ism beyond PPARγ activation. Indeed, candesartan was
shown to improve insulin sensitivity through PPARγ-
independent mechanism and to increase insulin content
in pancreatic beta-cells by attenuating oxidative stressing individual angiotensin receptor blocker with losartan
Candesartan Telmisartan Olmesartan
1.02 (0.98-1.06) 1.01 (0.97-1.05) 1.07 (1.02-1.12)
0.92 (0.86-0.99) 0.95 (0.89-1.01) 1.09 (1.01-1.18)
1.00 (0.95-1.05) 0.98 (0.94-1.03) 1.08 (1.02-1.14)
0.99 (0.94-1.04) 1.00 (0.96-1.05) 1.06 (1.00-1.13)
0.99 (0.95-1.02) 0.98 (0.95-1.02) 1.07 (1.02-1.11)
1.03 (0.93-1.14) 1.09 (0.97-1.22) 1.13 (0.98-1.31)
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have been shown to exert various anti-diabetic effects
other than PPARγ activation, including augmentation of
blood flow to muscle, direct modulation of insulin signal-
ing and up-regulation of glucose transporter expression in
muscle, reduction of islet fibrosis through inhibition of
TGF-β, and activation of AMPK/SIRT1 pathway [31-35].
These data, together with our observation, support het-
erogeneous anti-diabetic effects of ARBs.
Our study has some unique strength. First, this is cur-
rently the only study comparing diabetes risk for individual
ARB. Second, this study is a nationwide population-based
cohort study. The huge sample size and long duration of
follow-up enable this study adequately powered to detect
difference among ARBs. Third, the intention-to-treat
analysis preserves the baseline comparability of the treat-
ment groups, reduces the potential bias due to drug
switching or discontinuation, and provides a conservative
estimate. Therefore, the results provided real-life estima-
tions of diabetes risk associated with individual ARB,
which have important clinical implications. Diabetes is a
strong risk factor of cardiovascular disease, renal failure,
and retinopathy which imposes enormous economic
burden to the health care system [36-38]. The changed
diabetes incidence with different ARB therapy would
translate directly to mortality and medical costs. Fourth,
different analytic strategies, including the ITT and exclu-
sive user analyses, showed similar results and indicated an
internal consistency among these results.
Our study has some limitations. First, this is an observa-
tional study but not a randomized clinical trial. Therefore,
the association between individual ARBs and new-onset
diabetes may be affected by unknown or unmeasured con-
founders. Laboratory and anthropometric data such as
fasting glucose or body mass index were not available in
the NHI database. However, these factors are unlikely to
confound the results since physicians did not prescribe
specific ARB according to these factors. Furthermore, our
analyses have been fully adjusted for these baseline co-
morbidities. Second, imperfect adherence to therapy or
discontinuation of therapy could have attenuated our
intention-to-treat effect estimate. Third, the definition of
new-onset diabetes was made according to the ICD-9-CM
code but not by screening tests. Although the definition
algorithm using ICD-9-CM diagnosis code has a high
positive predictive value, some diagnoses of diabetes might
be missed. Nevertheless, the magnitude of increased risk
associated with olmesartan changed little (from 7% to 5%)
when more strict definition (diagnosis code plus anti-
diabetic therapy) was applied in the sensitivity analysis.
The under-estimation due to un-diagnosed diabetes or la-
tent diabetes should be minimal.
In conclusion, we found a small but significantly in-
creased diabetes incidence in olmesartan initiators ascompared to losartan initiators in a large nationwide
population-based cohort. Telmisartan was not associated
with reduced diabetes incidence. These findings suggest
heterogeneous diabetes risks associated with different
ARBs beyond a class effect, but the difference in diabetes
risk does not seem to correlate with PPARγ activation ac-
tivities. Further study is needed affirm this observation.
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